FATE THERAPEUTICS INC (FATE)
Data as of , from SEC Form 4 filings.
See up to 3 months of FATE. The 7-day demo opens the 1M and 3M ranges and puts FATE on your watchlist.
Start 7-day demoLatest FATE insider trades
- Cindy Tahl - OfficerOpen-market sale$95K
Bahram Valamehr - OfficerOpen-market sale$108K
About FATE THERAPEUTICS INC (FATE)
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
- SAN DIEGO, CA
- 161
- 2013
- XNAS
https://www.fatetherapeutics.comSEC filings for FATE on EDGAR
FATE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 82,747 | $204K |
FATE insider transactions (Form 4)
5331 Form 4 filings on record, the earliest from Dec 16, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Cindy Tahl - Officer | Open-market sale | Common Stock | 38,800 | $2.46 footnote F2 | $95K | |
| ||||||
| Bahram Valamehr - Officer | Open-market sale | Common Stock | 43,947 | $2.46 footnote F2 | $108K | |
| ||||||
| Redmile Group, LLC - Director | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
| Michael Stewart Lee - Director | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
| Yuan Xu | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
 Karin Jooss | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
 Robert S. Epstein | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
| Shefali Agarwal | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
| Matt Abernethy | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
 William H. Rastetter | Grant or award | Stock Option (Right to Buy) | 87,900 | $0.00 | - | |
| Laura Hamill | Grant or award | Stock Option (Right to Buy) | 175,800 | $0.00 | - | |
| Cindy Tahl - Officer | Open-market sale | Common Stock | 25,590 | $1.88 footnote F2 | $48K | |
| ||||||
| Bahram Valamehr - Officer | Open-market sale | Common Stock | 28,946 | $1.88 footnote F2 | $54K | |
| ||||||
| Cindy Tahl - Officer | Option exercise | Common Stock | 122,220 | $1.32 | $161K | |
| Cindy Tahl - Officer | Option exercise | Common Stock | 44,444 | $1.05 | $47K | |
| Cindy Tahl - Officer | Option exercise | Stock Option (Right to Buy) | 122,220 | $0.00 | - | |
| Cindy Tahl - Officer | Option exercise | Stock Option (Right to Buy) | 44,444 | $0.00 | - | |
| Robert S. Epstein | Option exercise | Common Stock | 25,000 | $1.69 | $42K | |
| Robert S. Epstein | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| William H. Rastetter | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| William H. Rastetter | Option exercise | Common Stock | 25,000 | $1.69 | $42K | |
| Redmile Group, LLC - Director | Other | Cash-settled Swaps | 266,280 | $0.00 | - | |
| Redmile Group, LLC - Director | Other | Cash-settled Swaps | 266,280 | $0.00 | - | |
| Redmile Group, LLC - Director | Other | Common Stock | 8,977,624 | $0.00 footnote F1 | - | |
| Redmile Group, LLC - Director | Other | Common Stock | 8,977,624 | $0.00 footnote F1 | - | |
| Redmile Group, LLC - Director | Other | Pre-Funded Warrants to Purchase Common Stock | 3,691,324 | $0.00 footnote F1 | - | |
| Redmile Group, LLC - Director | Other | Pre-Funded Warrants to Purchase Common Stock | 3,691,324 | $0.00 footnote F1 | - | |
| Redmile Group, LLC - Director | Other | Cash-settled Swaps | 266,280 | $0.00 footnote F9 | - | |
| Redmile Group, LLC - Director | Other | Cash-settled Swaps | 266,280 | $0.00 footnote F9 | - | |
| Redmile Group, LLC - Director | Other | Class A Convertible Preferred Stock | 162,013 | $0.00 footnote F1 | - | |
| Redmile Group, LLC - Director | Other | Class A Convertible Preferred Stock | 162,013 | $0.00 footnote F1 | - | |
| ||||||
| Cindy Tahl - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - | |
| Cindy Tahl - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | $0.00 | - | |
| Kamal Adawi - Officer | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Kamal Adawi - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Bahram Valamehr - Officer | Grant or award | Common Stock | 335,000 | $0.00 | - | |
| Bahram Valamehr - Officer | Grant or award | Stock Option (Right to Buy) | 1,300,000 | $0.00 | - | |
| Cindy Tahl - Officer | Open-market sale | Common Stock | 10,589 | $1.06 footnote F2 | $11K | |
| ||||||
| Bahram Valamehr - Officer | Open-market sale | Common Stock | 5,190 | $1.07 footnote F2 | $6K | |
| ||||||
| Kamal Adawi - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Kamal Adawi - Officer | Grant or award | Stock Option (Right to Buy) | 375,000 | $0.00 | - | |
| Cindy Tahl - Officer | Open-market sale | Common Stock | 9,037 | $1.06 | $10K | |
| Bahram Valamehr - Officer | Open-market sale | Common Stock | 14,466 | $1.06 | $15K | |
| Robert S. Epstein | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| John Mendlein | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| William H. Rastetter | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Redmile Group, LLC - Director | Other | Common Stock | 1,084,936 | $1.68 | $1.82M | |
| Redmile Group, LLC - Director | Other | Common Stock | 1,084,936 | $1.68 | $1.82M | |
| Redmile Group, LLC - Director | Open-market sale | Common Stock | 341,633 | $1.68 | $574K | |
| Redmile Group, LLC - Director | Open-market purchase | Common Stock | 397,964 | $1.68 | $669K | |
| Redmile Group, LLC - Director | Other | Class A Convertible Preferred Stock | 116,261 | $8.40 | $977K | |
| Redmile Group, LLC - Director | Other | Class A Convertible Preferred Stock | 116,261 | $8.40 | $977K | |
| Redmile Group, LLC - Director | Other | Cash-settled Swaps | 56,331 | $1.68 | $95K | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Item 8.01, 9.01
Recent FATE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Valamehr Bahram | Officer | 43,947 | $108K | View on EDGAR | |
| TAHL CINDY | Officer | 38,800 | $95K |
FATE insider trading FAQ
What is the latest insider trade for FATE?
FATE THERAPEUTICS INC (FATE) had 2 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for FATE runs to 31 Form 4 filings, the earliest from 2024-12-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying FATE stock?
No insider purchases of FATE were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling FATE stock?
2 insider sales of FATE were filed in the last 90 days, totaling $204K.
Where can I see FATE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects FATE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Cindy Tahl view on EDGAR
- - Bahram Valamehr view on EDGAR
- - Redmile Group, LLC view on EDGAR
- - Michael Stewart Lee view on EDGAR
- - Yuan Xu view on EDGAR
- - Karin Jooss view on EDGAR
- - Robert S. Epstein view on EDGAR
- - Shefali Agarwal view on EDGAR
- - Matt Abernethy view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where FATE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow FATE with a 7-day demo
- FATE on your watchlist
- Every FATE Form 4 filing on record
- Up to 3 months of FATE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
